跳至主要内容

Hemolysis Test

 Hemolysis test: refers to the hemolysis and red blood cell aggregation caused by pharmaceutical preparations. Hemolytic reactions include immune hemolysis and non-immune hemolysis.

1. Prepare 2% Red Blood Cells

Baoding rabbits, draw blood from the heart 5 m, add 0.2 ml of anticoagulant EDTA, wash with PBS, centrifuge to remove the white blood cells on the surface, until the supernatant does not show red, discard the supernatant, take 1 ml and add 50 ml of PBS.

2. Prepare Materials


Adjust the concentration of different kinds of materials to 800, 400, 200, 100, 50 and 25 ug/mb with PBS solution, and the concentration of gold clusters to 50, 25, 12.5, 6.25, 3.15 ug/ml.

3. Experimental Process

Before each use of red blood cells, wash with PBS until there is no obvious red (slightly yellow) in the supernatant, and draw 200ul of the substrate. Release to 10ml for use.

Mix 0.5ml of the material with 0.5ml of 2% red blood cell solution, stand still at room temperature for 3 hours, and then centrifuge at 10050 r/min for 3 minutes. Take out 100ul to 96-well plate, use 570nm wavelength to detect. Water and PBS were used as positive and negative controls, respectively. Two parallels for each sample.

Hemolysis rate (%) = (sample absorption-negative control absorption) / (positive control absorption-negative control absorption) x 100%. A hemolysis rate of more than 5% is regarded as hemolysis.

Contact Us:

Email : marketing@medicilon.com

Tel : +44 1223 981 792 (Europe)

+82 (0)70-8269-5849 (South Korea)

08044216898 (Japan)

+86 021 58591500 (China)

Website: https://www.medicilon.com

Related Articles:

Hemolysis Assay Labs

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文